Scott Braunstein, Marinus CEO (Marinus via YouTube)
September 14, 2020 04:01 PM EDTUpdated September 15, 06:24 AM
R&D
FDA+

Mar­i­nus ex­ecs her­ald the re­birth of the one-drug biotech as a pos­i­tive PhI­II read­out ar­rives for a rare dis­ease

John Carroll

Editor & Founder

Af­ter a long, neck-snap­ping ride full of spills, thrills and dis­mal chills, the ex­ecs now run­ning small-cap biotech Mar­i­nus $MRNS say they …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Bio­gen gets $250M in Roy­al­ty Phar­ma deal for Phase 3 lu­pus pro­gram

Af­ter pass­ing on M&A of­fers, Abcuro rais­es $200M in bid to be­come com­mer­cial drug­mak­er

Ab­b­Vie pens an­oth­er T cell en­gager deal, this time with Xilio

Ex­clu­sive: Longevi­ty start­up tar­gets rene­gade pro­teins linked to di­a­betes and obe­si­ty

Spring­Works lands FDA ap­proval for nerve tu­mor treat­ment

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times